KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash from Investing Activities: 2016-2024

Historic Cash from Investing Activities for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $1.9 billion.

  • Moderna's Cash from Investing Activities fell 2.91% to $700.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 25.38%. This contributed to the annual value of $1.9 billion for FY2024, which is 53.66% down from last year.
  • Latest data reveals that Moderna reported Cash from Investing Activities of $1.9 billion as of FY2024, which was down 53.66% from $4.2 billion recorded in FY2023.
  • Moderna's 5-year Cash from Investing Activities high stood at $4.2 billion for FY2023, and its period low was -$8.5 billion during FY2021.
  • Its 3-year average for Cash from Investing Activities is $326.3 million, with a median of $1.9 billion in 2024.
  • Per our database at Business Quant, Moderna's Cash from Investing Activities tumbled by 11,046.67% in 2020 and then surged by 181.26% in 2023.
  • Over the past 5 years, Moderna's Cash from Investing Activities (Yearly) stood at -$1.7 billion in 2020, then plummeted by 409.75% to -$8.5 billion in 2021, then soared by 39.27% to -$5.2 billion in 2022, then skyrocketed by 181.26% to $4.2 billion in 2023, then crashed by 53.66% to $1.9 billion in 2024.